rAAt (inhaled) Arriva/Hyland Immuno.
Arriva Pharmaceuticals Inc and Hyland Immuno are developing a nebulized formulation of the recombinant alpha1-antitrypsin (rAAT) for the potential treatment of respiratory disorders, including emphysema, asthma and chronic obstructive pulmonary disease. The therapy, as a nebulized formulation, is currently undergoing phase II clinical trials.
Brown
William M
WM
Paddock Laboratories Inc, 3940 Quebec Avenue North, Minneapolis, MN 55427, USA. wbrown@paddocklabs.com
D017321:Clinical Trials, Phase I as Topic; D004345:Drug Industry; D006801:Humans; D001239:Inhalation; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D013329:Structure-Activity Relationship; D000515:alpha 1-Antitrypsin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000515:alpha 1-Antitrypsin